Announcements Trials
Browse Landscape

Phase

Phase NA 19Phase 2 7Phase 4 4Phase 3 3Phase 2/3 3

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Vulvodynia 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Dyspareunia 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Water × Clear all
NCT04799249 2024-08-01

PRESERVE 2

G1 Therapeutics, Inc.

Phase 3 Completed
194 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT01539317 2017-04-14

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

OHSU Knight Cancer Institute

Phase 3 Completed
50 enrolled 9 charts
Breast

Breast Neoplasms, Dyspareunia, Vulvodynia

NCT01479244 2017-02-27

PRESENT

Galena Biopharma, Inc.

Phase 3 Completed
758 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡